Close



Apr 2, 2024 07:00PM
Mar 26, 2024 07:00PM
Mar 20, 2024 07:00PM
Mar 12, 2024 06:30AM
Mar 12, 2024 06:30AM
Jan 17, 2024 06:00AM
Jan 17, 2024 06:00AM MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
Dec 21, 2023 06:00PM
Dec 6, 2023 06:00PM
Nov 20, 2023 05:23AM
Nov 19, 2023 06:00PM
Oct 27, 2023 05:20AM
Oct 27, 2023 01:00AM
Oct 11, 2023 05:50AM Medicinova (MNOV) Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 and Riluzole
Oct 10, 2023 07:00PM
Oct 5, 2023 04:46AM
Oct 4, 2023 07:00PM
Sep 28, 2023 05:24AM
Sep 27, 2023 07:00PM
Sep 27, 2023 07:00PM
Aug 17, 2023 07:00PM MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
Aug 17, 2023 05:34AM
Aug 16, 2023 07:00PM
Aug 16, 2023 05:14AM
Aug 15, 2023 07:00PM
Aug 15, 2023 01:52AM
Aug 14, 2023 07:00PM
Aug 14, 2023 07:00PM MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
Jun 29, 2023 06:03AM
Jun 29, 2023 06:00AM
Jun 29, 2023 06:00AM
May 14, 2023 07:00PM
May 1, 2023 05:22AM
Apr 30, 2023 07:00PM
Apr 30, 2023 07:00PM MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
Mar 9, 2023 06:00PM
Mar 9, 2023 06:00PM
Feb 21, 2023 05:51AM
Feb 20, 2023 06:00PM
Feb 20, 2023 06:00PM
Feb 8, 2023 06:00PM
Feb 8, 2023 06:00PM MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
Jan 31, 2023 05:30AM
Jan 30, 2023 06:00PM
Jan 30, 2023 06:00PM
Jan 12, 2023 06:00PM
Jan 12, 2023 06:00PM
Jan 10, 2023 10:00PM
Jan 10, 2023 10:00PM MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
Jan 10, 2023 04:39AM

251,013 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All